Collectively, our studies illuminate the role of ATAD2 as a facilitator of ovarian cancer growth and metastasis and indicate that ATAD2 inhibitors, used either alone or in combination with CENPE inhibitors, may represent therapeutic option for treating ovarian cancer patients. Here, ATAD2 is linked to ovarian carcinoma.